The Array Discovery Platform Includes the Following Technologies:

Our scientists use the Array Discovery Platform, an integrated suite of drug discovery and development technologies, to create drug candidates and to conduct preclinical and clinical development. A critical capability within the Array Discovery Platform is our proprietary software, which enables our scientists to share information across our company, analyze databases of existing drugs, generate novel predictive databases and design novel drugs with potential competitive advantages over current therapies. We use in vitro and in vivo predictive pharmacodynamic and pharmacokinetic models to select compounds for potential development. Early in the drug discovery process, our scientists engineer desirable drug characteristics, such as improved potency, specificity and dosing regimen and reduced side effect profile, into drug candidates. The resulting compounds are tested for safety, efficacy and metabolism to select the most promising clinical candidates.

Our expanding development capabilities include innovative clinical trials designs that incorporate early markers of biological activity; in-house cGMP facilities, which allow us to rapidly produce clinical drug supplies; clinical development strategies that incorporate trials in diseases that provide rapid proof of concept; therapeutically focused clinical teams that drive rapid protocol development, clinical site selection, trial initiation and monitoring, and study result evaluation.

We believe our drug discovery and development approach can significantly improve on the industry's existing clinical attrition rates through our use of:

• Proprietary chemoinformatic databases that relate chemical structure to compound development potential;
• Multiple lead generation strategies including high throughput screening, virtual screening and proprietary de novo design software;
• State-of-the-art protein x-ray crystallography, structural databases and computational modeling;
• An extensive battery of in vivo and in vitro metabolic and safety drug profiling assays;
• A company-wide electronic laboratory notebook that enables our scientists to collect, analyze and share information across the organization; and
• Innovative clinical trial designs, incorporating markers of biological activity.